{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T18:02:11Z","timestamp":1789581731266,"version":"build-2803163510"},"reference-count":136,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Neuroimmune diseases comprise a heterogeneous group of disorders in which B cells, plasmablasts, plasma cells, autoantibodies, and T cells contribute differently to tissue injury. Although B-cell-directed biologics have improved disease control, some patients continue to experience treatment-refractory activity, relapse after treatment withdrawal, or cumulative neurological disability. Chimeric antigen receptor T-cell (CAR-T cell) therapy offers a means of achieving deeper and potentially sustained depletion of defined pathogenic immune-cell compartments. This narrative review integrates the mechanistic rationale, target selection, platform design, published human experience, and translational challenges of CAR-T cell therapy in neuroimmune diseases. Current strategies predominantly target CD19-expressing B-lineage cells or BCMA-expressing antibody-secreting cells; these therapeutic targets are distinct from disease autoantigens, and their relevance depends on the immunopathology of each disorder. CAR design, persistence, lymphodepletion, and the use of integrating or transient expression platforms further influence treatment activity and risk. Clinical development remains uneven across indications. Myasthenia gravis has the most diverse clinical experience, encompassing integrating CD19-, BCMA-, and dual CD19\/BCMA-targeted products, together with a transient BCMA-targeted mRNA platform evaluated in a randomized, placebo-controlled phase 2b study. In neuromyelitis optica spectrum disorder, an open-label phase 1 study has demonstrated early clinical and immunological activity of BCMA-targeted CAR-T cells. Evidence in multiple sclerosis and stiff-person syndrome is derived from individual reports, small early-phase studies, and conference data, whereas experience in other neuroimmune diseases remains limited to isolated reports or small case series. Across indications, interpretation is constrained by small and heterogeneous cohorts, limited follow-up, and the predominance of uncontrolled observations. Major translational considerations include target breadth and selectivity, the contribution of lymphodepletion, the disease-dependent relevance of central nervous system trafficking, acute and delayed toxicity, patient selection, manufacturing feasibility, biomarker development, and standardized long-term outcome assessment. CAR-T cell therapy has shown preliminary clinical activity in selected patients with refractory neuroimmune diseases, but its comparative efficacy, durability, and long-term safety remain undefined. It therefore remains investigational for most neuroimmune indications.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1913956","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T17:11:21Z","timestamp":1789578681000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Chimeric antigen receptor T-cell therapy in neuroimmune diseases: mechanistic rationale, clinical experience, and translational challenges"],"prefix":"10.3389","volume":"17","author":[{"given":"Yaqiao","family":"Yi","sequence":"first","affiliation":[{"name":"School of Traditional Chinese Medicine, Hunan University of Chinese Medicine","place":["Changsha, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Xiao","sequence":"additional","affiliation":[{"name":"School of Traditional Chinese Medicine, Hunan University of Chinese Medicine","place":["Changsha, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yitong","family":"Yin","sequence":"additional","affiliation":[{"name":"School of Traditional Chinese Medicine, Hunan University of Chinese Medicine","place":["Changsha, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Zeng","sequence":"additional","affiliation":[{"name":"School of Traditional Chinese Medicine, Hunan University of Chinese Medicine","place":["Changsha, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingqing","family":"Yan","sequence":"additional","affiliation":[{"name":"School of Traditional Chinese Medicine, Hunan University of Chinese Medicine","place":["Changsha, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonghe","family":"Wu","sequence":"additional","affiliation":[{"name":"School of Traditional Chinese Medicine, Hunan University of Chinese Medicine","place":["Changsha, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kailin","family":"Yang","sequence":"additional","affiliation":[{"name":"Institute of Basic Research in Traditional Chinese Medicine, Hunan Academy of Chinese Medicine","place":["Changsha, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilong","family":"Fu","sequence":"additional","affiliation":[{"name":"People\u2019s Hospital of Ningxiang City, Hunan University of Chinese Medicine","place":["Changsha, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Xu","sequence":"additional","affiliation":[{"name":"School of Traditional Chinese Medicine, Hunan Traditional Chinese Medical College","place":["Zhuzhou, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiongmei","family":"Zhang","sequence":"additional","affiliation":[{"name":"School of Artificial Intelligence, Sun Yat-sen University","place":["Zhuhai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-083122-044829","article-title":"B cell-directed therapy in autoimmunity","volume":"42","author":"Abeles","year":"2024","journal-title":"Annu Rev Immunol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(24)00140-6","article-title":"B cell-targeting chimeric antigen receptor T cells as an emerging therapy in neuroimmunological diseases","volume":"23","author":"Haghikia","year":"2024","journal-title":"Lancet Neurol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/cei\/uxae031","article-title":"Disrupting B and T-cell collaboration in autoimmune disease: T-cell engagers versus CAR T-cell therapy","volume":"217","author":"Shah","year":"2024","journal-title":"Clin Exp Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200080","article-title":"CAR-T cell\u2013mediated B-cell depletion in central nervous system autoimmunity","volume":"10","author":"Gupta","year":"2023","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-024-01035-3","article-title":"Chimeric antigen receptor T cell therapy for autoimmune disease","volume":"24","author":"Chung","year":"2024","journal-title":"Nat Rev Immunol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.medj.2024.03.002","article-title":"CD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosis","volume":"5","author":"Fischbach","year":"2024","journal-title":"Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.adj9730","article-title":"Single-cell analysis of anti-BCMA CAR T cell therapy in patients with central nervous system autoimmunity","volume":"9","author":"Qin","year":"2024","journal-title":"Sci Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2026.101026","article-title":"Single-cell profiling of immune reset in patients with refractory generalized myasthenia gravis receiving autologous CD19\/BCMA CAR-T cell therapy","volume":"7","author":"Ruan","year":"2026","journal-title":"Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(23)00194-1","article-title":"Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b\/2a study","volume":"22","author":"Granit","year":"2023","journal-title":"Lancet Neurol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-04171-y","article-title":"BCMA-directed mRNA CAR T cell therapy for myasthenia gravis: a randomized, double-blind, placebo-controlled phase 2b trial","volume":"32","author":"Vu","year":"2026","journal-title":"Nat Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41392-022-01278-3","article-title":"Anti-BCMA CAR T-cell therapy CT103A in relapsed or refractory AQP4-IgG seropositive neuromyelitis optica spectrum disorders: phase 1 trial interim results","volume":"8","author":"Qin","year":"2023","journal-title":"Signal Transduction Targeted Ther"},{"key":"B12","doi-asserted-by":"publisher","first-page":"6414","DOI":"10.1016\/j.cell.2025.09.020","article-title":"Anti-BCMA CAR-T therapy in patients with progressive multiple sclerosis","volume":"188","author":"Qin","year":"2025","journal-title":"Cell"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2403227121","article-title":"Successful use of anti-CD19 CAR T cells in severe treatment-refractory stiff-person syndrome","volume":"121","author":"Faissner","year":"2024","journal-title":"Proc Natl Acad Sci"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200479","article-title":"Anti-CD19 CAR T-cell therapy in advanced stiff-person syndrome and concomitant myasthenia gravis","volume":"12","author":"Ayzenberg","year":"2025","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B15","doi-asserted-by":"publisher","first-page":"5919","DOI":"10.1212\/WNL.0000000000217905","article-title":"Miv-cel CD19 CAR T-cell therapy shows efficacy and safety in stiff person syndrome in a pivotal, multicenter, phase 2 study (KYSA-8) (LS2.008)","volume":"106","author":"Piquet","year":"2026","journal-title":"Neurology"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-024-12642-4","article-title":"Chimeric antigen receptor T-cell therapy for autoimmune diseases of the central nervous system: a systematic literature review","volume":"271","author":"Konitsioti","year":"2024","journal-title":"J Neurol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1604987","article-title":"Immunological microenvironment and targeted therapeutics in multiple sclerosis: new insights in crosstalk between immune niches and CNS","volume":"16","author":"Sun","year":"2025","journal-title":"Front Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/ene.70236","article-title":"Baseline cognitive and neurological status does not modify the occurrence of ICANS in CAR T-cell therapy for aggressive B-cell lymphoma","volume":"32","author":"Ursu","year":"2025","journal-title":"Eur J Neurol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-020-10237-3","article-title":"Neurological updates: neurological complications of CAR-T therapy","volume":"268","author":"Tallantyre","year":"2021","journal-title":"J Neurol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s00296-024-05772-5","article-title":"Safety and efficacy of CAR-T cell therapy in patients with autoimmune diseases: a systematic review","volume":"45","author":"Kattamuri","year":"2025","journal-title":"Rheumatol Int"},{"key":"B21","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/s41573-025-01349-4","article-title":"Roads and detours for CAR T cell therapy in autoimmune diseases","volume":"25","author":"Avouac","year":"2026","journal-title":"Nat Rev Drug Discov"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awae362","article-title":"Current state and perspectives of CAR T cell therapy in central nervous system diseases","volume":"148","author":"Pfeffer","year":"2025","journal-title":"Brain"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102476","article-title":"Innovative cellular therapies for autoimmune diseases: expert-based position statement and clinical practice recommendations from the EBMT practice harmonization and guidelines committee","volume":"69","author":"Greco","year":"2024","journal-title":"eClinicalMedicine"},{"key":"B24","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1002\/cpt.70352","article-title":"Translating B-cell and plasma-cell targeting from oncology to autoimmunity: modalities, quantitative bridging, and a development roadmap","volume":"120","author":"Yuan","year":"2026","journal-title":"Clin Pharmacol Ther"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurol.2024.08.003","article-title":"Predicting the future of autoimmune encephalitides","volume":"180","author":"Guasp","year":"2024","journal-title":"Rev Neurol (Paris)"},{"key":"B26","first-page":"47","article-title":"Role of B cells and pathogenic autoantibodies in autoimmune CNS and PNS neurologic diseases","volume-title":"Handbook of Clinical Neurology","author":"Stathopoulos","year":"2026"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf6756","article-title":"Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease","volume":"353","author":"Ellebrecht","year":"2016","journal-title":"Science"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-022-01637-z","article-title":"Precision targeting of autoantigen-specific B cells in muscle-specific tyrosine kinase myasthenia gravis with chimeric autoantibody receptor T cells","volume":"41","author":"Oh","year":"2023","journal-title":"Nat Biotechnol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1708712","article-title":"Antibody-mediated encephalitis","volume":"378","author":"Dalmau","year":"2018","journal-title":"N Engl J Med"},{"key":"B30","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1038\/s41582-024-01012-3","article-title":"Stiff-person syndrome and related disorders \u2014 diagnosis, mechanisms and therapies","volume":"20","author":"Dalakas","year":"2024","journal-title":"Nat Rev Neurol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00218-0","article-title":"Myelin-oligodendrocyte glycoprotein antibody-associated disease","volume":"20","author":"Marignier","year":"2021","journal-title":"Lancet Neurol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s40364-017-0102-y","article-title":"Engineering CAR-T cells","volume":"5","author":"Zhang","year":"2017","journal-title":"biomark Res"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2025.12.006","article-title":"Mapping clinical CAR-T cells: insights from scRNA-seq","volume":"32","author":"Meehl","year":"2026","journal-title":"Trends Mol Med"},{"key":"B34","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1158\/2159-8290.CD-20-0756","article-title":"A critical role for fas-mediated off-target tumor killing in T-cell immunotherapy","volume":"11","author":"Upadhyay","year":"2021","journal-title":"Cancer Discov"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1007\/BF02918252","article-title":"Fas expression and apoptosis in human B cells","volume":"15","author":"Schattner","year":"1996","journal-title":"Immunol Res"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurol.2024.07.005","article-title":"CAR T-cell-associated neurotoxicity: a comprehensive review","volume":"180","author":"Ursu","year":"2024","journal-title":"Rev Neurol (Paris)"},{"key":"B37","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s11899-023-00687-7","article-title":"CAR-T cell therapy: the efficacy and toxicity balance","volume":"18","author":"Chohan","year":"2023","journal-title":"Curr Hematol Malig Rep"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.aat6753","article-title":"Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function","volume":"11","author":"Salter","year":"2018","journal-title":"Sci Signaling"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2016.01.021","article-title":"Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells","volume":"44","author":"Kawalekar","year":"2016","journal-title":"Immunity"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2021.10.037","article-title":"Hypogammaglobulinemia after chimeric antigen receptor (CAR) T-cell therapy: characteristics, management, and future directions","volume":"10","author":"Wat","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2023.08.002","article-title":"CAR T cells ignite antitumor immunity","volume":"44","author":"Alizadeh","year":"2023","journal-title":"Trends Immunol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-024-00764-7","article-title":"Targeting TGF\u03b2-activated kinase-1 activation in microglia reduces CAR T immune effector cell-associated neurotoxicity syndrome","volume":"5","author":"Vinnakota","year":"2024","journal-title":"Nat Cancer"},{"key":"B43","doi-asserted-by":"publisher","first-page":"3238","DOI":"10.1016\/j.cell.2025.03.041","article-title":"Immunotherapy-related cognitive impairment after CAR T cell therapy in mice","volume":"188","author":"Geraghty","year":"2025","journal-title":"Cell"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1080\/14737159.2025.2565274","article-title":"Cell avidity in CAR-T cell therapy","volume":"25","author":"Chen","year":"2025","journal-title":"Expert Rev Mol Diagn"},{"key":"B45","doi-asserted-by":"publisher","first-page":"3148","DOI":"10.1016\/j.cell.2023.06.002","article-title":"Vaccine-boosted CAR T crosstalk with host immunity to reject tumors with antigen heterogeneity","volume":"186","author":"Ma","year":"2023","journal-title":"Cell"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1465191","article-title":"Application of novel CAR technologies to improve treatment of autoimmune disease","volume":"15","author":"Cheever","year":"2024","journal-title":"Front Immunol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.927153","article-title":"CAR-T cell therapy in hematological Malignancies: current opportunities and challenges","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Immunol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12943-025-02515-3","article-title":"Next-generation CAR-T cells design: leveraging tumor features for enhanced efficacy","volume":"25","author":"Lei","year":"2025","journal-title":"Mol Cancer"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.omton.2024.200833","article-title":"Regulation of CAR transgene expression to design semiautonomous CAR-T","volume":"32","author":"G\u0142owacki","year":"2024","journal-title":"Mol Ther Oncol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.934343","article-title":"Regulatory CAR-T cells in autoimmune diseases: progress and current challenges","volume":"13","author":"Riet","year":"2022","journal-title":"Front Immunol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.112379","article-title":"Generation of CAR-TSCM: CAR-T with super clutch","volume":"136","author":"Hu","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s13045-022-01255-x","article-title":"Rewiring mitochondrial metabolism to counteract exhaustion of CAR-T cells","volume":"15","author":"Huang","year":"2022","journal-title":"J Hematol Oncol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.103941","article-title":"Improving CAR-T immunotherapy: overcoming the challenges of T cell exhaustion","volume":"77","author":"Gumber","year":"2022","journal-title":"eBioMedicine"},{"key":"B54","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1186\/s12967-025-06718-6","article-title":"Innovative approaches to CAR-T cell therapy: the role of lipid metabolism pathways","volume":"23","author":"Guo","year":"2025","journal-title":"J Transl Med"},{"key":"B55","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s40164-024-00535-1","article-title":"Fueling CARs: metabolic strategies to enhance CAR T-cell therapy","volume":"13","author":"Van der Vreken","year":"2024","journal-title":"Exp Hematol Oncol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"H1","DOI":"10.1530\/VB-19-0033","article-title":"Immune cell trafficking across the blood-brain barrier in the absence and presence of neuroinflammation","volume":"2","author":"Marchetti","year":"2020","journal-title":"Vasc Biol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial activation and blood\u2013brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discov"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N Engl J Med"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606468","article-title":"Ocrelizumab versus placebo in primary progressive multiple sclerosis","volume":"376","author":"Montalban","year":"2017","journal-title":"N Engl J Med"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30475-6","article-title":"Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study","volume":"391","author":"Kappos","year":"2018","journal-title":"Lancet"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01126-1","article-title":"CAR T-cell therapy in autoimmune diseases","volume":"402","author":"Schett","year":"2023","journal-title":"Lancet"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-024-01139-z","article-title":"Advancements and challenges in CAR T cell therapy in autoimmune diseases","volume":"20","author":"Schett","year":"2024","journal-title":"Nat Rev Rheumatol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awab093","article-title":"Formation and immunomodulatory function of meningeal B cell aggregates in progressive CNS autoimmunity","volume":"144","author":"Mitsdoerffer","year":"2021","journal-title":"Brain"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2026.2682293","article-title":"Chimeric antigen receptor T-cell therapy induces complete remission in a patient with concurrent CLL with CNS involvement and multiple sclerosis","volume":"67","author":"Murphy","year":"2026","journal-title":"Leuk Lymphoma"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.ard.2025.03.018","article-title":"Relapse after anti-CD19 CAR T-cell therapy in a patient with severe rheumatoid arthritis and multiple sclerosis effectively treated by autologous stem cell transplantation","volume":"84","author":"Pecher","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1002\/ana.27029","article-title":"The role of chimeric antigen receptor T-cell therapy in immune-mediated neurological diseases","volume":"96","author":"Brittain","year":"2024","journal-title":"Ann Neurol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1007\/s11684-025-1191-x","article-title":"B cell targeted CAR-T therapy for autoimmune diseases","volume":"19","author":"Li","year":"2025","journal-title":"MedScience"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1177\/13524585251364140","article-title":"Anti-B cell CAR-T therapy in multiple sclerosis is simply a more profound immunoablation? Yes","volume":"31","author":"Dersch","year":"2025","journal-title":"Mult Scler J"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1177\/13524585251364144","article-title":"Anti-B-cell CAR-T therapy in multiple sclerosis is simply a more profound immunoablation? No","volume":"31","author":"Bruno","year":"2025","journal-title":"Mult Scler J"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1177\/13524585251370085","article-title":"Anti-B-cell CAR-T therapy in multiple sclerosis is simply a more profound immunoablation? Commentary","volume":"31","author":"Massey","year":"2025","journal-title":"Mult Scler J"},{"key":"B71","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1001\/jamaneurol.2024.3818","article-title":"Current and future roles of chimeric antigen receptor T-cell therapy in neurology: a review","volume":"82","author":"Ismail","year":"2025","journal-title":"JAMA Neurol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1177\/1352458512459685","article-title":"EDSS variability before randomization may limit treatment discovery in primary progressive MS","volume":"19","author":"Zhang","year":"2013","journal-title":"Mult Scler J"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1737202","article-title":"Adapting CAR-T and CAR-treg cancer therapies for autoimmunity: innovations and challenges","volume":"17","author":"Lovelace","year":"2026","journal-title":"Front Immunol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/j.lrr.2026.100577","article-title":"Delayed fatal neurotoxicity in post CAR-T cell therapy for multiple myeloma, a case report","volume":"25","author":"Khoudari","year":"2026","journal-title":"Leuk Res Rep"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-020-02840-x","article-title":"Progressive multifocal leukoencephalopathy after CAR T therapy","volume":"112","author":"Sdrimas","year":"2020","journal-title":"Int J Hematol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s41408-025-01441-3","article-title":"Clinical course, risk factors and mitigating strategies for immune effector cell-associated late onset neurotoxicities after ciltacabtagene autoleucel CAR-T in multiple myeloma","volume":"16","author":"Lim","year":"2025","journal-title":"Blood Cancer J"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02826-w","article-title":"T cell lymphoma and secondary primary Malignancy risk after commercial CAR T cell therapy","volume":"30","author":"Ghilardi","year":"2024","journal-title":"Nat Med"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-020-01521-5","article-title":"Recommendations for screening, monitoring, prevention, and prophylaxis of infections in adult and pediatric patients receiving CAR T-cell therapy: a position paper","volume":"49","author":"Los-Arcos","year":"2021","journal-title":"Infection"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/j.ero.2025.11.011","article-title":"Fertility and pregnancy outcomes after CAR T-cell therapy: insights from a systematic review","volume":"2","author":"Kremer","year":"2026","journal-title":"EULAR Rheumatol Open"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awaf170","article-title":"The case for targeting latent and lytic epstein-barr virus infection in multiple sclerosis","volume":"148","author":"Giovannoni","year":"2025","journal-title":"Brain"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.3724\/abbs.2026026","article-title":"The EBV-MS paradigm: beyond molecular mimicry toward new therapeutic strategies","volume":"58","author":"Xie","year":"2026","journal-title":"Acta Biochim Biophys Sin"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0000000000001494","article-title":"Investigational approaches to multiple sclerosis therapy","volume":"39","author":"Boeckers","year":"2026","journal-title":"Curr Opin Neurol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2024.104970","article-title":"Guidance for use of neurofilament light chain as a cerebrospinal fluid and blood biomarker in multiple sclerosis management","volume":"101","author":"Freedman","year":"2024","journal-title":"eBioMedicine"},{"key":"B84","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1001\/jamaneurol.2022.5250","article-title":"Serum glial fibrillary acidic protein compared with neurofilament light chain as a biomarker for disease progression in multiple sclerosis","volume":"80","author":"Meier","year":"2023","journal-title":"JAMA Neurol"},{"key":"B85","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s12974-025-03668-0","article-title":"CAR T cells as novel therapeutic strategy for multiple sclerosis and other neuroimmune disorders","volume":"23","author":"Samadzadeh","year":"2025","journal-title":"J Neuroinflamm"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-024-00470-5","article-title":"CAR-T therapy for multiple sclerosis enters US trials for first time","author":"Mullard","year":"2024","journal-title":"Nature"},{"key":"B87","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s12974-025-03662-6","article-title":"CAR T cell therapy in autoantibody-mediated neurological disorders: a promising strategy","volume":"23","author":"Wen","year":"2026","journal-title":"J Neuroinflamm"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2024.101250","article-title":"CAR-T cell manufacturing landscape\u2014lessons from the past decade and considerations for early clinical development","volume":"32","author":"Dias","year":"2024","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2025.1709474","article-title":"Cellular therapy in neuromyelitis optica spectrum disorder","volume":"16","author":"Zhong","year":"2025","journal-title":"Front Neurol"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26178538","article-title":"Myelin oligodendrocyte glycoprotein antibody-associated disease: pathophysiology, clinical patterns, and therapeutic challenges of intractable and severe forms","volume":"26","author":"Misu","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-023-11910-z","article-title":"Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) \u2013 revised recommendations of the neuromyelitis optica study group (NEMOS). Part II: attack therapy and long-term management","volume":"271","author":"K\u00fcmpfel","year":"2024","journal-title":"J Neurol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2026.125982","article-title":"Chimeric antigen receptor T-cell therapy in neurological disorders: emerging applications, evidence, and challenges","volume":"487","author":"Luo","year":"2026","journal-title":"J Neurol Sci"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.70415","article-title":"CAR T-cell therapy in neurology: a scoping review of neuro-oncology, autoimmune diseases & neurotoxicity","volume":"13","author":"Alqaisi","year":"2026","journal-title":"Ann Clin Transl Neurol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000727","article-title":"Clinical utility of AQP4-IgG titers and measures of complement-mediated cell killing in NMOSD","volume":"7","author":"Jitprapaikulsan","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B95","article-title":"The future unfolded: CAR T cells and the transformation of treatment algorithms in autoimmune neurology","volume-title":"Handbook of Clinical Neurology","author":"Mougiakakos","year":"2026"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(23)00211-9","article-title":"Are CAR T cells the answer to myasthenia gravis therapy","volume":"22","author":"Meisel","year":"2023","journal-title":"Lancet Neurol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1002\/mus.70222","article-title":"Chimeric antigen receptor T-cells in myasthenia gravis: advances, safety challenges, and future directions","volume":"73","author":"Hegelmaier","year":"2026","journal-title":"Muscle Nerve"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.2147\/ITT.S492062","article-title":"Advances in B cell targeting for treating muscle-specific tyrosine kinase-associated myasthenia gravis","volume":"13","author":"Hu","year":"2024","journal-title":"ImmunoTargets Ther"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(23)00375-7","article-title":"Anti-CD19 CAR T cells for refractory myasthenia gravis","volume":"22","author":"Haghikia","year":"2023","journal-title":"Lancet Neurol"},{"key":"B100","doi-asserted-by":"publisher","first-page":"6515","DOI":"10.1212\/WNL.0000000000206520","article-title":"Successful treatment of concomitant myasthenia gravis and lambert-eaton myasthenic syndrome with autologous CD19-targeted CAR-T cells (P4-14.006)","volume":"102","author":"Motte","year":"2024","journal-title":"Neurology"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2024-226017","article-title":"Clinical efficacy and autoantibody seroconversion with CD19-CAR T cell therapy in a patient with rheumatoid arthritis and coexisting myasthenia gravis","volume":"83","author":"Haghikia","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1038\/s44321-024-00043-z","article-title":"B cell lineage reconstitution underlies CAR-T cell therapeutic efficacy in patients with refractory myasthenia gravis","volume":"16","author":"Tian","year":"2024","journal-title":"EMBO Mol Med"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-024-12367-4","article-title":"Bispecific BCMA\/CD19 targeted CAR-T cell therapy forces sustained disappearance of symptoms and anti-acetylcholine receptor antibodies in refractory myasthenia gravis: a case report","volume":"271","author":"Zhang","year":"2024","journal-title":"J Neurol"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103621","article-title":"Anti-BCMA\/CD19 CAR T cell therapy in patients with refractory generalized myasthenia gravis: a single-arm, phase 1 trial","volume":"90","author":"Zhang","year":"2025","journal-title":"EClinicalMedicine"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aeb6424","article-title":"BCMA\/CD19 CAR T cell therapy for refractory myasthenia gravis: proteomic signatures and single-cell transcriptomics of disease flares","volume":"12","author":"Huang","year":"2026","journal-title":"Sci Adv"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.70167","article-title":"Durability of response to B-cell maturation antigen-directed mRNA cell therapy in myasthenia gravis","volume":"12","author":"Chahin","year":"2025","journal-title":"Ann Clin Transl Neurol"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-04170-z","article-title":"BCMA-directed mRNA CAR-T cell therapy for myasthenia gravis: exploratory biomarker analysis of a placebo-controlled phase 2b trial","volume":"32","author":"Fedak","year":"2026","journal-title":"Nat Med"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1111\/ene.70609","article-title":"Long-term outcomes in stiff person spectrum disorder","volume":"33","author":"Mangioris","year":"2026","journal-title":"Eur J Neurol"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200292","article-title":"CD19-directed CAR T-cells in a patient with refractory MOGAD: clinical and immunologic follow-up for 1 year","volume":"11","author":"Cabrera-Maqueda","year":"2024","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2025.100776","article-title":"Chimeric antigen receptor T cells in treatment-refractory DAGLA antibody-associated encephalitis","volume":"6","author":"Hegelmaier","year":"2025","journal-title":"Med"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.70414","article-title":"Anti- CD19 CAR T cells in autoimmune encephalitis: inflammation controlled, neurodegeneration unchecked","volume":"13","author":"Mougiakakos","year":"2026","journal-title":"Ann Clin Transl Neurol"},{"key":"B112","doi-asserted-by":"publisher","first-page":"5084","DOI":"10.1016\/j.cell.2023.10.001","article-title":"Chimeric autoantibody receptor T cells deplete NMDA receptor-specific B cells","volume":"186","author":"Reincke","year":"2023","journal-title":"Cell"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1016\/j.hlife.2024.05.005","article-title":"BCMA-CD19 bispecific CAR-T therapy in refractory chronic inflammatory demyelinating polyneuropathy","volume":"2","author":"Zhang","year":"2024","journal-title":"hLife"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2025.100704","article-title":"Anti-BCMA CAR-T cell therapy in relapsed\/refractory chronic inflammatory demyelinating polyneuropathy","volume":"6","author":"Dong","year":"2025","journal-title":"Med"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(25)00199-1","article-title":"CD19-targeted CAR T-cell therapy for treatment-refractory autoimmune neuropathies","volume":"24","author":"Motte","year":"2025","journal-title":"Lancet Neurol"},{"key":"B116","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/s41408-025-01384-9","article-title":"Chronic inflammatory demyelinating polyneuropathy (CIDP) after cilta-cel therapy","volume":"15","author":"Korenkov","year":"2025","journal-title":"Blood Cancer J"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101794","article-title":"Anti-CD19 CAR-T cells are effective in severe idiopathic lambert-eaton myasthenic syndrome","volume":"5","author":"Wickel","year":"2024","journal-title":"Cell Rep Med"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1755797","article-title":"Successful fresh formulation CD19 CAR-T cell therapy for GAD65 antibody-mediated cerebellar ataxia. A case report","volume":"17","author":"Vaisvilas","year":"2026","journal-title":"Front Immunol"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1097\/PHM.0000000000002736","article-title":"Convergence of infection, chimeric antigen receptor T-cell therapy, and neuralgic amyotrophy: a case report","volume":"104","author":"Dettloff","year":"2025","journal-title":"Am J Phys Med Rehabil"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2026.102145","article-title":"CAR T cell therapy: autoimmune neurological uses and neurotoxicities","volume":"40","author":"Friedman","year":"2026","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00146","article-title":"Multi targeted CAR-T cell therapies for B-cell Malignancies","volume":"9","author":"Shah","year":"2019","journal-title":"Front Oncol"},{"key":"B122","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.coi.2019.07.011","article-title":"Antigen-specific tolerance to self-antigens in protein replacement therapy, gene therapy and autoimmunity","volume":"61","author":"Steinman","year":"2019","journal-title":"Curr Opin Immunol"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.12.003","article-title":"Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European society for blood and marrow transplantation (EBMT) and the joint accreditation committee of ISCT and EBMT (JACIE) and the European haematology association (EHA)","volume":"33","author":"Hayden","year":"2022","journal-title":"Ann Oncol"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2024000534","article-title":"Late complications and long-term care of adult CAR T-cell patients","volume":"2024","author":"Bishop","year":"2024","journal-title":"Hematology"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00032","article-title":"Vaccination of adults with cancer: ASCO guideline","volume":"42","author":"Kamboj","year":"2024","journal-title":"J Clin Oncol"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2401361","article-title":"Risk of second tumors and T-cell lymphoma after CAR T-cell therapy","volume":"390","author":"Hamilton","year":"2024","journal-title":"N Engl J Med"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-024-00955-x","article-title":"Neurofilaments as biomarkers in neurological disorders \u2014 towards clinical application","volume":"20","author":"Khalil","year":"2024","journal-title":"Nat Rev Neurol"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25126295","article-title":"Tau, glial fibrillary acidic protein, and neurofilament light chain as brain protein biomarkers in cerebrospinal fluid and blood for diagnosis of neurobiological diseases","volume":"25","author":"Park","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B129","doi-asserted-by":"publisher","first-page":"1055.e1-1055.e23","DOI":"10.1016\/j.jtct.2026.05.005","article-title":"Expert panel review and practical guidance on biomarker testing with engineered immune effector cells","volume":"32","author":"Blumenberg","year":"2026","journal-title":"Transplant Cell Ther"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2024.09.008","article-title":"Successful generation of fully human, second generation, anti-CD19 CAR T cells for clinical use in patients with diverse autoimmune disorders","volume":"27","author":"Mougiakakos","year":"2025","journal-title":"Cytotherapy"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.7150\/thno.125983","article-title":"CAR-T manufacturing reduces heterogeneity between CIDP and multiple myeloma patient-derived T cells","volume":"16","author":"Wang","year":"2026","journal-title":"Theranostics"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1126\/science.ads8473","article-title":"In vivo CAR T cell generation to treat cancer and autoimmune disease","volume":"388","author":"Hunter","year":"2025","journal-title":"Science"},{"key":"B133","doi-asserted-by":"publisher","first-page":"S2666-6367(26)00362-3","DOI":"10.1016\/j.jtct.2026.05.019","article-title":"Next-generation CAR-T therapies: from personalized anticancer drugs to broadly applicable disease-modifying treatments","volume":"19","author":"Wen","year":"2026","journal-title":"Transplant Cell Ther"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1802718","article-title":"Advancements and expanding applications of CAR-T cell therapy","volume":"17","author":"Zhang","year":"2026","journal-title":"Front Immunol"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1016\/j.trim.2024.102137","article-title":"Outcomes with chimeric antigen receptor T-cell therapy in rheumatological disorders: a systematic review","volume":"87","author":"Zulfiqar","year":"2024","journal-title":"Transpl Immunol"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2025.578651","article-title":"An updated, comprehensive meta-analysis of the treatment of anti-NMDAR encephalitis: analysis, equipoise, and the urgent need for evidence over anecdote","volume":"405","author":"Hoshina","year":"2025","journal-title":"J Neuroimmunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1913956\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T17:11:24Z","timestamp":1789578684000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1913956\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,16]]},"references-count":136,"alternative-id":["10.3389\/fimmu.2026.1913956"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1913956","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,16]]},"article-number":"1913956"}}